Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October

By Maxx Chatsko - Nov 7, 2018 at 11:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company de-risked the development of its potential blockbuster hepatitis B drug for a cool $250 million. Investors thought the price was too low.

What happened

Shares of Arrowhead Pharmaceuticals ( ARWR 3.19% ) fell more than 33% last month, according to data provided by S&P Global Market Intelligence. In addition to broad market volatility, investors were disappointed by an announcement that the company accepted a helping hand from Johnson & Johnson -- a hand that also happened to be extending an up-front payment of $175 million for access to a potential blockbuster.

While linking up with Johnson & Johnson will significantly de-risk the development and commercialization of a promising hepatitis B treatment called ARO-HBV, investors think the data reported in September were so impressive that an up-front payment of $175 million wasn't enough.

A question mark on a red card sitting against a chalkboard.

Image source: Getty Images.

So what

Arrowhead Pharmaceuticals stock has been on fire in 2018 on multiple positive developments from its pipeline. That optimism was confirmed in September when the company reported solid data for ARO-HBV from an early-stage trial, which showed that one in eight patients receiving the drug experienced a 99.9% drop in detectable circulating hepatitis B virus. The worst response observed was 93%. That strongly hints that the drug candidate will have a bright future, and investors think it will become a blockbuster with annual sales of more than $1 billion.

Of course, developing drugs -- and successfully commercializing them -- is very expensive. That nudged Arrowhead Pharmaceuticals to partner with Johnson & Johnson subsidiary Janssen to ensure ARO-HBV has the best chances of success if and when it gains marketing approval. The partnership could earn the originator up to $3.5 billion in milestone payments to go along with an up-front payment of $175 million and an equity investment of $75 million. It can earn royalty payments on top of that.

The $250 million investment will significantly de-risk the future for Arrowhead Pharmaceuticals, including the development of other promising pipeline candidates that are unrelated to the partnership with Janssen. That shouldn't be overlooked considering the company ended June with just $28 million in cash and compiled an operating loss of $44 million in the prior nine months. Nonetheless, investors apparently thought that the money changing hands wasn't enough.

Now what

It appears that investors have come around to their senses since the end of October. Shares of Arrowhead Pharmaceuticals rose 25% in the first week of November and are now up more than 330% since the beginning of 2018. While the company has a long road ahead of it that doesn't guarantee success, padding the balance sheet with nondilutive cash means there's a lot less risk going forward. Now investors simply have to wait for further updates from the pipeline.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arrowhead Pharmaceuticals, Inc. Stock Quote
Arrowhead Pharmaceuticals, Inc.
ARWR
$73.96 (3.19%) $2.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
652%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.